TY  - JOUR
AU  - Fidler, S
AU  - Lewin, S
AU  - Deeks, S
AU  - Sogaard, OS
AU  - Vandekerckhove, L
AU  - Collins, S
AU  - Kelly, D
AU  - Singh, J
AU  - Caskey, M
AU  - Frater, J
Y2  - 2021/05/03
Y1  - 2021/03/01
SN  - 2055-6640
UR  - http://hdl.handle.net/11343/272396
AB  - This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
LA  - English
PB  - MEDISCRIPT LTD
T1  - HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
DO  - 10.1016/j.jve.2020.100025
IS  - Journal of virus eradication
VL  - 7
IS  - 1
SP  - 100025-
L1  - /bitstream/handle/11343/272396/PMC7719279.pdf?sequence=1&isAllowed=y
ER  -